OSE Immunotherapeutics
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
OSE | PA
Overview
Corporate Details
- ISIN(s):
- FR0012127173 (+2 more)
- LEI:
- 969500HIUWVGY6NZSM05
- Country:
- France
- Address:
- 22 BOULEVARD BENONI GOULLIN, 44200 NANTES
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
OSE Immunotherapeutics is an integrated, clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's primary areas of focus are immuno-oncology (IO) and immuno-inflammation (I&I). Its research and development platform is centered on identifying specific targets to activate or regulate the immune response. OSE Immunotherapeutics advances its product candidates through early- to mid-stage clinical development before seeking partnerships for late-stage development and commercialization. The company maintains a pipeline of proprietary clinical assets aimed at addressing high unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-16 19:58 |
Interim Report
RAPPORT FINANCIER SEMESTRIEL 2025
|
French | 1.2 MB | ||
| 2025-10-15 19:00 |
Earnings Release
OSE Immunotherapeutics Reports First Half 2025 Financial Results
|
English | 215.4 KB | ||
| 2025-10-15 19:00 |
Earnings Release
OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025
|
French | 215.6 KB | ||
| 2025-10-09 15:57 |
Major Shareholding Notification
Franchissement de seuils
|
French | 120.1 KB | ||
| 2025-09-30 19:30 |
Post-Annual General Meeting Information
Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairma…
|
English | 250.6 KB | ||
| 2025-09-30 19:30 |
Post-Annual General Meeting Information
Renouvellement complet du Conseil d'administration Élection du Dr Markus Cappel…
|
French | 209.8 KB | ||
| 2025-09-02 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Informations relatives au nombre total de droits de vote et d’actions composan…
|
French | 195.2 KB | ||
| 2025-07-17 18:30 |
Regulatory News Service
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
|
English | 201.6 KB | ||
| 2025-07-17 18:30 |
Report Publication Announcement
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
|
French | 212.2 KB | ||
| 2025-06-20 19:30 |
Legal Proceedings Report
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene…
|
English | 226.5 KB | ||
| 2025-06-20 19:30 |
Pre-Annual General Meeting Information
OSE Immunotherapeutics réaffirme son engagement à tenir une Assemblée Générale …
|
French | 204.2 KB | ||
| 2025-06-11 18:30 |
Regulatory News Service
AJOURNEMENT DE L’ASSEMBLÉE GÉNÉRALE INITIALEMENT CONVOQUEE POUR LE 25 JUIN 2025
|
French | 201.6 KB | ||
| 2025-06-11 18:30 |
Pre-Annual General Meeting Information
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
|
English | 204.6 KB | ||
| 2025-06-09 08:00 |
Pre-Annual General Meeting Information
MISE À JOUR DES MODALITÉS DE L’ASSEMBLÉE GÉNÉRALE
|
French | 178.6 KB | ||
| 2025-06-09 08:00 |
Pre-Annual General Meeting Information
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
|
English | 184.3 KB |
Automate Your Workflow. Get a real-time feed of all OSE Immunotherapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OSE Immunotherapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OSE Immunotherapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-19 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,800.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-13 | N/A | Other | Sell | 6,369 | 45,879.09 EUR |
| 2024-06-03 | N/A | Other | Sell | 40,000 | 314,512.00 EUR |
